secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2022-12-02T23:59:59+00:00
Accession:  0001193125-22-297163
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics reports 55% reduction in convulsive seizures in Phase 1/2a study of STK-001 in Dravet syndrome
--------------------------------------------------------------------------------

- 55% median reduction in convulsive seizure frequency from baseline in 6 patients treated with three doses of 45mg STK-001.
- 5/6 (83%) patients showed reductions; 4/6 (67%) had >50% reduction from baseline.
- STK-001 up to 45mg well-tolerated; 27% (15/55) of patients had treatment-related AEs, all mild/moderate, no withdrawals.
- Reductions in seizure frequency maintained in SWALLOWTAIL open-label extension; trend toward improvement in executive function (BRIEF-P).
- One-year BUTTERFLY observational data showed little change in cognition without STK-001 treatment, highlighting disease progression.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312522297163/0001193125-22-297163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312522297163/d428421d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-297163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer